Vascular Research Group, Salford Royal NHS Foundation Trust, Salford, United Kingdom.
Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom.
PLoS One. 2018 Oct 26;13(10):e0206469. doi: 10.1371/journal.pone.0206469. eCollection 2018.
The benefits of dialysis in older people with ESKD are not clear. We prospectively evaluated whether dialysis has survival advantage compared to conservative care (CC) in older people who were medically suitable for dialysis therapy.
This was a prospective observational study of CKD patients aged ≥75 years when eGFR first reached ≤15ml/min/1.73m2. Hazard ratios (HR) for death were compared between patients who chose dialysis versus conservative care (CC) from when first seen in pre-dialysis clinic (eGFR ≤15ml/min/1.73m2), and when initiation of dialysis was first considered (eGFR ≤10ml/min/1.73m2). Patients with co-morbidities likely to significantly reduce life expectancy such as advanced heart failure, advanced dementia, and malignancy, were excluded.
There were 204 patients (123 dialysis, 81 CC). 115 went on to record eGFR of ≤10ml/min/1.73m2 (73 dialysis, 42 CC). The median survival from eGFR first ≤15ml/min/1.73m2 for the dialysis and CC groups were 42 (33-50) months and 31 (21-41) months. The adjusted hazard ratio (HR) for death in the dialysis group compared to CC was 0.61 (0.41-0.61, p = 0.01). The median survival from eGFR first ≤10ml/min/1.73m2 for dialysis and CC group were 36 (25-47) months and 12 (0-5) months. The adjusted HR for death in the dialysis group compared to CC was 0.36 (0.21-0.62, p <0.001).
Dialysis confers a survival benefit in older patients medically suitable for dialysis. This study is novel in being both prospective and in excluding patients with co-morbidities which may limit suitability for dialysis and life expectancy. A future focus on quality of life is needed to establish the true benefits of dialysis in older people.
终末期肾病(ESKD)老年患者接受透析治疗的获益并不明确。本研究前瞻性评估了对于适合透析治疗的老年患者,与保守治疗(CC)相比,透析治疗是否具有生存优势。
本研究为前瞻性观察性研究,纳入首次 eGFR 降至≤15ml/min/1.73m2 时年龄≥75 岁的 CKD 患者。比较在开始透析前(eGFR≤15ml/min/1.73m2)和首次考虑开始透析时(eGFR≤10ml/min/1.73m2)选择透析与 CC 的患者之间的死亡风险比(HR)。排除合并可能显著降低预期寿命的合并症(如晚期心力衰竭、晚期痴呆和恶性肿瘤)的患者。
共纳入 204 例患者(123 例接受透析治疗,81 例接受 CC)。115 例患者记录到 eGFR≤10ml/min/1.73m2(73 例接受透析治疗,42 例接受 CC)。从首次 eGFR≤15ml/min/1.73m2 开始,透析组和 CC 组的中位生存时间分别为 42(33-50)个月和 31(21-41)个月。与 CC 相比,透析组的死亡调整 HR 为 0.61(0.41-0.61,p=0.01)。从首次 eGFR≤10ml/min/1.73m2 开始,透析组和 CC 组的中位生存时间分别为 36(25-47)个月和 12(0-5)个月。与 CC 相比,透析组的死亡调整 HR 为 0.36(0.21-0.62,p<0.001)。
对于适合透析的老年患者,透析治疗可带来生存获益。本研究的新颖之处在于前瞻性研究和排除了可能限制透析适用性和预期寿命的合并症患者。需要进一步关注生活质量,以确定透析治疗在老年人中的真正获益。